Welcome to our dedicated page for Xenetic Biosciences SEC filings (Ticker: XBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DNase platforms, PolyXen drug extensions and early-stage CAR T research make Xenetic Biosciences鈥� disclosures uniquely detailed鈥攁nd hard to navigate. Clinical trial updates, royalty waterfalls and dilution clauses often span hundreds of pages, leaving even seasoned analysts searching for context. If you have ever typed 鈥淴enetic Biosciences SEC filings explained simply鈥� into a browser, you already know the challenge.
Stock Titan solves that problem. Our AI parses every document the moment it hits EDGAR, turning jargon into clear takeaways you can act on. Want 鈥淴enetic Biosciences insider trading Form 4 transactions鈥� or need the latest 鈥淴enetic Biosciences quarterly earnings report 10-Q filing鈥�? They appear here with side-by-side AI commentary. AG真人官方-time alerts track 鈥淴enetic Biosciences Form 4 insider transactions real-time,鈥� while smart summaries spotlight trial-phase spending, milestone payments and cash-runway projections buried deep in MD&A sections.
Use this page to:
- Access a 鈥淴enetic Biosciences annual report 10-K simplified鈥� with highlighted pipeline risks
- Dive into 鈥淴enetic Biosciences earnings report filing analysis鈥� for revenue from licensing partners
- Monitor 鈥淴enetic Biosciences proxy statement executive compensation鈥� to gauge alignment with shareholders
- Receive 鈥淴enetic Biosciences 8-K material events explained鈥� within minutes of release
- Track 鈥淴enetic Biosciences executive stock transactions Form 4鈥� before key trial readouts
- Save hours by 鈥渦nderstanding Xenetic Biosciences SEC documents with AI鈥� rather than line-by-line review
Whether you鈥檙e assessing dilution risk, validating NET-targeted trial data or comparing quarter-over-quarter cash burn, our comprehensive coverage and AI-powered summaries keep you ahead without drowning in paperwork.
Xenetic Biosciences reported a narrowing net loss driven by lower operating expenses while continuing to receive royalties from Takeda. Royalty revenue was $589,897 for the quarter and $1,183,158 for the six months ended June 30, 2025. The company recorded a net loss of $688,703 for the quarter and $1,591,844 for the six-month period. Cash totaled $4,779,846 at June 30, 2025 and working capital was approximately $4.5 million, while total assets were $5.35 million.
Operating costs fell year-over-year as R&D and general and administrative expenses declined, largely reflecting lower personnel and severance-related items recognized in 2024. Management states existing resources are adequate to fund operations for at least twelve months from issuance of these financial statements, but the company anticipates the need for additional capital longer term to advance its DNase clinical program and other initiatives.
FAQ
What is the current stock price of Xenetic Biosciences (XBIO)?
What is the market cap of Xenetic Biosciences (XBIO)?
